Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 2:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 136 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Controlled and matched powder Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

NCT02836496
View directory record Official record
Conditions
Hypereosinophilic Syndrome
Interventions
Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or prednisone), Placebo matching OCS capsules
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
San Diego, California • New Haven, Connecticut • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 8, 2026, 2:14 AM EDT
Completed Phase 3 Interventional Results available

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation

NCT03930732
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 80 Years
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
51
States / cities
Andalusia, Alabama • Birmingham, Alabama • Dothan, Alabama + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 8, 2026, 2:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Randomized, Double-Blind, Controlled Trial to Assess the Efficacy of a Fortetropin Supplement in Improving Symptoms of Osteoarthritis

NCT06021665
View directory record Official record
Conditions
Osteoarthritis
Interventions
Fortetropin supplement, Cheese protein
Other
Lead sponsor
MYOS Corp
Industry
Eligibility
50 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 8, 2026, 2:14 AM EDT
Recruiting Not applicable Interventional

Effects of Ketone Ester Consumption on Exercise Tolerance and Cardiac Function

NCT06078683
View directory record Official record
Conditions
Type 2 Diabetes, Ketone Body Metabolism, Ketones, Metabolism
Interventions
Ketone Ester Acute, Placebo Acute
Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 8, 2026, 2:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria

NCT04629170
View directory record Official record
Conditions
Healthy, Enteric Hyperoxaluria
Interventions
SYNB8802, Placebo
Drug
Lead sponsor
Synlogic
Industry
Eligibility
18 Years to 74 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
4
States / cities
Tucson, Arizona • Tampa, Florida • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2024 · Synced Oct 8, 2026, 2:14 AM EDT
Recruiting Phase 2 Interventional

A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma

NCT07532265
View directory record Official record
Conditions
Severe Asthma
Interventions
Frevecitinib, Placebo
Drug
Lead sponsor
Kinaset Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
14
States / cities
Lancaster, California • San Jose, California • Brandon, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 8, 2026, 2:14 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis

NCT05084963
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
IRL201104, Placebo
Drug
Lead sponsor
Revolo Biotherapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
23
States / cities
Little Rock, Arkansas • Murrieta, California • Centennial, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 8, 2026, 2:14 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes

NCT03885245
View directory record Official record
Conditions
Asthma, Obesity
Interventions
L-ctirulline, Matching Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 8, 2026, 2:14 AM EDT
Completed Phase 2 Interventional Results available

Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder

NCT02909959
View directory record Official record
Conditions
Autism Spectrum Disorder, Autistic Disorder, Neurodevelopmental Disorder, Childhood Developmental Disorders, Pervasive
Interventions
Sulforaphane, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
13 Years to 30 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Carrboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 8, 2026, 2:14 AM EDT
Terminated Phase 4 Interventional Results available

Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism

NCT04558125
View directory record Official record
Conditions
Pulmonary Embolism, COVID
Interventions
TNKase, Placebo, Enoxaparin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 8, 2026, 2:14 AM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients

NCT05954988
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
LTI-03, Placebo
Drug
Lead sponsor
Rein Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Birmingham, Alabama • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 8, 2026, 2:14 AM EDT
Recruiting Phase 1Phase 2 Interventional

Herbal Evaluation Of Artemisia Annua For Small Intestinal Bacterial Overgrowth

NCT06721884
View directory record Official record
Conditions
Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
Interventions
Artemisia Annua Leaf, placebo
Dietary Supplement · Other
Lead sponsor
National University of Natural Medicine
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 8, 2026, 2:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Of PF-05175157 In Healthy Volunteers

NCT01274663
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-05175157 or Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Oct 8, 2026, 2:14 AM EDT
Active, not recruiting Not applicable Interventional

Electrical Neuromodulation for Modifying Spinal Network Involved in Spasticity

NCT07792616
View directory record Official record
Conditions
Spinal Cord Injuries (Complete and Incomplete), Spinal Cord Injury, Spinal Cord Injury Cervical, Spinal Cord Injury Thoracic, Spinal Cord Injuries, Spasticity, Spasm, Muscle Spasticity, Muscle Hypertonia, Muscle Spasm
Interventions
Transcutaneous spinal stimulation at 30 Hz, Transcutaneous spinal stimulation at 75 Hz, Tizanidine, Baclofen, Placebo
Other · Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 8, 2026, 2:14 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza

NCT01793883
View directory record Official record
Conditions
Influenza
Interventions
40 mg Laninamivir Octanoate, 80 mg Laninamivir Octanoate, Placebo
Drug
Lead sponsor
Biota Scientific Management Pty Ltd
Industry
Eligibility
18 Years to 64 Years
Enrollment
639 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
70
States / cities
Scottsboro, Alabama • Camp Verde, Arizona • Chandler, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced Oct 8, 2026, 2:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluate Effects of Sprinkled Format REDUCOSE in a Carbohydrate-rich, Mixed Meal on Post-prandial Glycemia

NCT04877366
View directory record Official record
Conditions
Dietary Supplement
Interventions
Dietary Supplement: Sprinkled Format REDUCOSE., Reference control, Active comparator
Dietary Supplement · Other
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 8, 2026, 2:14 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

NCT01356602
View directory record Official record
Conditions
Acute Gouty Arthritis
Interventions
Canakinumab pre-filled syringe, Canakinumab lyophilized powder, Triamcinolone Acetonide, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
69
States / cities
Anniston, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 62 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Oct 8, 2026, 2:14 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

SOAR-2: Intervening in Obesity Through Reduction of Dietary Branched Chain Amino Acids

NCT04424537
View directory record Official record
Conditions
Obesity, Diabetes
Interventions
Control diet, Low branched-chain amino acids(BCAA) diet, Low protein diet
Dietary Supplement
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
30 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 8, 2026, 2:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Escalation Study of GSK2838232 in Healthy Subjects

NCT01802918
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2838232, Placebo, Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 8, 2026, 2:14 AM EDT
Terminated Phase 3 Interventional Results available

A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

NCT02967692
View directory record Official record
Conditions
Melanoma
Interventions
Spartalizumab, Placebo, Dabrafenib, Trametinib
Biological · Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
12
States / cities
Encinitas, California • Orange, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 8, 2026, 2:14 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day

NCT03234465
View directory record Official record
Conditions
Oral Mucositis
Interventions
AG013, Placebo
Biological · Other
Lead sponsor
Oragenics, Inc.
Industry
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
27
States / cities
Farmington, Connecticut • Newark, Delaware • Orlando, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 8, 2026, 2:14 AM EDT
Completed Phase 1 Interventional

Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose Study

NCT01956305
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
DS-7309, placebo, Metformin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Oct 8, 2026, 2:14 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3)

NCT05764239
View directory record Official record
Conditions
Phenylketonuria
Interventions
SYNB1934v1, Placebo
Drug
Lead sponsor
Synlogic
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
14
States / cities
Culver City, California • Orange, California • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 8, 2026, 2:14 AM EDT
Completed Phase 3 Interventional Results available

Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler

NCT02980133
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate, Fluticasone Propionate/Salmeterol, Placebo MDPI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
77
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 59 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 8, 2026, 2:14 AM EDT